4-(2-cyano-4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester | 256951-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-cyano-4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(2-cyano-4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 256951-75-4
• 化学式: C₁₇H₁₉FN₂O₂
• 分子量: 302.348
• InChiKey: HFDZQABCRFINAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-cyano-4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 在 palladium on activated charcoal 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 生成 (4R)-N-[3-[4-(2-cyano-4-fluorophenyl)piperidin-1-yl]propyl]-4-(3,4-difluorophenyl)-1,6-dimethyl-2-oxo-3,4-dihydropyridine-5-carboxamide
  参考文献：
  名称：

  Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones

  摘要：

  A series of alpha(1a) receptor antagonists derived from a 4-aryl-3,4-dihydropyridine-2-one heterocycle is disclosed. Potency in the low nanomolar to picomolar range along with high selectivity was obtained. In vivo efficacy in a prostate contraction model in rats was observed with a few derivatives. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00696-4
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 正丁基锂 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 生成 4-(2-cyano-4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Alpha 1A adrenergic receptor antagonists

  摘要：

  这项发明涉及某些新颖化合物及其衍生物，它们的合成以及它们作为α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织之一是围绕尿道内膜的组织。因此，这些化合物的一个用途是通过减少尿液流动的阻碍，为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。

  公开号：

  US06339090B1

文献信息

• Oxazolidinones useful as alpha 1A adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06319932B1

  公开（公告）日：2001-11-20

  Novel oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  披露了新型恶唑烷酮化合物及其可药用的盐。这些化合物的合成及其作为α1a肾上腺素能受体拮抗剂的使用也进行了描述。这些化合物的一个应用是治疗良性前列腺增生。这些化合物在选择性地放松富含α1a受体亚型的平滑肌组织的能力方面是特异的，同时不引起低血压。这样的组织之一位于尿道内衬周围。因此，这些化合物的一个用途是为准切缓解患有良性前列腺增生的男性的症状，通过允许更顺畅的尿液流动。这些化合物的另一个用途是与人类5-α还原酶抑制剂化合物结合使用，从而使良性前列腺增生的急性症状和慢性症状均可得到缓解。
• Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06235759B1

  公开（公告）日：2001-05-22

  Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  揭示了新型二氢吡啶酮和吡咯酮化合物及其药用盐。描述了这些化合物的合成以及它们作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织包括尿道内膜周围的组织。因此，这些化合物的一个用途是通过允许尿液流动更畅顺来为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合使用，从而可以实现对良性前列腺增生影响的急性和慢性缓解。
• Oxazolidinones useful as alpha 1a adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06228870B1

  公开（公告）日：2001-05-08

  Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  揭示了新型羟甲基和烷氧基甲基噁唑烷酮化合物及其药用可接受盐。描述了这些化合物的合成及其作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生症。这些化合物在放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不引起低血压。这样的组织包括尿道内膜周围的组织。因此，这些化合物的一个用途是为患有良性前列腺增生症的男性提供急性缓解，从而减少尿液流动的阻碍。这些化合物的另一个用途是与人类5-α还原酶抑制剂化合物结合，以实现对良性前列腺增生症影响的急性和慢性缓解。
• [EN] ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
  申请人：MERCK & CO INC

  公开号：WO2000006565A1

  公开（公告）日：2000-02-10

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  本发明涉及某些新型化合物及其衍生物，它们的合成以及它们作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是治疗良性前列腺增生症。这些化合物在其选择性上具有放松充满α1a受体亚型的平滑肌组织的能力，而不会同时引起低血压。这样的组织可以在尿道内膜周围发现。因此，这些化合物的一个用途是为男性良性前列腺增生症提供急性缓解，从而使尿液流动更加顺畅。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生症的急性和慢性缓解。
• In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α_1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia
  作者：James C. Barrow、Philippe G. Nantermet、Harold G. Selnick、Kristen L. Glass、Kenneth E. Rittle、Kevin F. Gilbert、Thomas G. Steele、Carl F. Homnick、Roger M. Freidinger、Rick W. Ransom、Paul Kling、Duane Reiss、Theodore P. Broten、Terry W. Schorn、Raymond S. L. Chang、Stacey S. O'Malley、Timothy V. Olah、Joan D. Ellis、Andrea Barrish、Kelem Kassahun、Paula Leppert、Dhanapalan Nagarathnam、Carlos Forray

  DOI：10.1021/jm990612y

  日期：2000.7.1

  alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K-i values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1d) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.